Literature DB >> 19051139

MyoCell, a cell-based, autologous skeletal myoblast therapy for the treatment of cardiovascular diseases.

Husnain Kh Haider1, Ye Lei, Muhammad Ashraf.   

Abstract

Cell therapy is fast emerging as a potential therapeutic option in cardiovascular therapeutics. Because of their inherent myogenic differentiation potential, skeletal myoblasts (SkMs) have been extensively assessed in preclinical and clinical studies for their feasibility, safety and effectiveness for myocardial repair. Bioheart Inc is developing MyoCell, autologous SkMs delivered by MyoCath and MyoStar catheter delivery systems, for the treatment of cardiovascular diseases such as myocardial infarction and congestive heart failure. MyoCell is undergoing phase II/III clinical development and has so far demonstrated safety and efficacy, including improvements in cardiac function in phase I/II clinical trials.

Entities:  

Mesh：

Year:  2008        PMID： 19051139      PMCID： PMC2668534     

Source DB:  PubMed          Journal:  Curr Opin Mol Ther        ISSN： 1464-8431


  56 in total

1.  The real estate of myoblast cardiac transplantation: negative remodeling is associated with location.

Authors:  Jonathan D McCue; Cory Swingen; Tanya Feldberg; Gabe Caron; Adam Kolb; Christopher Denucci; Somnath Prabhu; Randy Motilall; Brian Breviu; Doris A Taylor
Journal:  J Heart Lung Transplant       Date:  2008-01       Impact factor: 10.247

2.  Cellular cardiomyoplasty improves diastolic properties of injured heart.

Authors:  B Z Atkins; M T Hueman; J Meuchel; K A Hutcheson; D D Glower; D A Taylor
Journal:  J Surg Res       Date:  1999-08       Impact factor: 2.192

3.  Angiopoietin-1 for myocardial angiogenesis: a comparison between delivery strategies.

Authors:  Lei Ye; Husnain Kh Haider; Shujia Jiang; Ru San Tan; Wee Chi Toh; RuoWen Ge; Eugene K W Sim
Journal:  Eur J Heart Fail       Date:  2006-12-22       Impact factor: 15.534

4.  Cell transplantation for the treatment of acute myocardial infarction using vascular endothelial growth factor-expressing skeletal myoblasts.

Authors:  K Suzuki; B Murtuza; R T Smolenski; I A Sammut; N Suzuki; Y Kaneda; M H Yacoub
Journal:  Circulation       Date:  2001-09-18       Impact factor: 29.690

5.  Mobilized bone marrow cells repair the infarcted heart, improving function and survival.

Authors:  D Orlic; J Kajstura; S Chimenti; F Limana; I Jakoniuk; F Quaini; B Nadal-Ginard; D M Bodine; A Leri; P Anversa
Journal:  Proc Natl Acad Sci U S A       Date:  2001-08-14       Impact factor: 11.205

6.  Pharmacologically preconditioned skeletal myoblasts are resistant to oxidative stress and promote angiomyogenesis via release of paracrine factors in the infarcted heart.

Authors:  Muhammad Idris Niagara; Husnain Kh Haider; Shujia Jiang; Muhammad Ashraf
Journal:  Circ Res       Date:  2007-01-18       Impact factor: 17.367

7.  Gene therapy for myocardial angiogenesis: with direct intramuscular gene transfer of naked deoxyribonucleic acid encoding vascular endothelial growth factor and cell transplantation of vascular endothelial growth factor transfected H9c2 myoblast.

Authors:  Tsutomu Sugimoto; Kiyoshige Inui; Yasuhisa Shimazaki
Journal:  Jpn J Thorac Cardiovasc Surg       Date:  2003-05

8.  Bone marrow cells adopt the cardiomyogenic fate in vivo.

Authors:  Marcello Rota; Jan Kajstura; Toru Hosoda; Claudia Bearzi; Serena Vitale; Grazia Esposito; Grazia Iaffaldano; M Elena Padin-Iruegas; Arantxa Gonzalez; Roberto Rizzi; Narissa Small; John Muraski; Roberto Alvarez; Xiongwen Chen; Konrad Urbanek; Roberto Bolli; Steven R Houser; Annarosa Leri; Mark A Sussman; Piero Anversa
Journal:  Proc Natl Acad Sci U S A       Date:  2007-10-26       Impact factor: 11.205

Review 9.  Cardiac stem cell-based myocardial regeneration: towards a translational approach.

Authors:  Daniele Torella; Ciro Indolfi; David F Goldspink; Georgina M Ellison
Journal:  Cardiovasc Hematol Agents Med Chem       Date:  2008-01

10.  Haematopoietic stem cells do not transdifferentiate into cardiac myocytes in myocardial infarcts.

Authors:  Charles E Murry; Mark H Soonpaa; Hans Reinecke; Hidehiro Nakajima; Hisako O Nakajima; Michael Rubart; Kishore B S Pasumarthi; Jitka Ismail Virag; Stephen H Bartelmez; Veronica Poppa; Gillian Bradford; Joshua D Dowell; David A Williams; Loren J Field
Journal:  Nature       Date:  2004-03-21       Impact factor: 49.962
View more
  11 in total

Review 1.  Signaling Pathways and Gene Regulatory Networks in Cardiomyocyte Differentiation.

Authors:  Abhirath Parikh; Jincheng Wu; Robert M Blanton; Emmanuel S Tzanakakis
Journal:  Tissue Eng Part B Rev       Date:  2015-05-11       Impact factor: 6.389

Review 2.  Scaffolds in the microbial resistant era: Fabrication, materials, properties and tissue engineering applications.

Authors:  Ángel Serrano-Aroca; Alba Cano-Vicent; Roser Sabater I Serra; Mohamed El-Tanani; AlaaAA Aljabali; Murtaza M Tambuwala; Yogendra Kumar Mishra
Journal:  Mater Today Bio       Date:  2022-08-30

3.  Optimized delivery system achieves enhanced endomyocardial stem cell retention.

Authors:  Atta Behfar; Jean-Pierre Latere; Jozef Bartunek; Christian Homsy; Dorothee Daro; Ruben J Crespo-Diaz; Paul G Stalboerger; Valerie Steenwinckel; Aymeric Seron; Margaret M Redfield; Andre Terzic
Journal:  Circ Cardiovasc Interv       Date:  2013-12-10       Impact factor: 6.546

Review 4.  Characterizing functional stem cell-cardiomyocyte interactions.

Authors:  Nenad Bursac; Robert D Kirkton; Luke C McSpadden; Brian Liau
Journal:  Regen Med       Date:  2010-01       Impact factor: 3.806

Review 5.  Coming to terms with tissue engineering and regenerative medicine in the lung.

Authors:  Y S Prakash; Daniel J Tschumperlin; Kurt R Stenmark
Journal:  Am J Physiol Lung Cell Mol Physiol       Date:  2015-08-07       Impact factor: 5.464

Review 6.  Regenerative Medicine: Charting a New Course in Wound Healing.

Authors:  Geoffrey C Gurtner; Mary Ann Chapman
Journal:  Adv Wound Care (New Rochelle)       Date:  2016-07-01       Impact factor: 4.730

Review 7.  Cell therapy for cardiovascular disease: a comparison of methods of delivery.

Authors:  Nabil Dib; Harris Khawaja; Samantha Varner; Megan McCarthy; Ann Campbell
Journal:  J Cardiovasc Transl Res       Date:  2010-12-23       Impact factor: 4.132

Review 8.  Challenges for heart disease stem cell therapy.

Authors:  Jane Hoover-Plow; Yanqing Gong
Journal:  Vasc Health Risk Manag       Date:  2012-02-17

Review 9.  Generation and Assessment of Functional Biomaterial Scaffolds for Applications in Cardiovascular Tissue Engineering and Regenerative Medicine.

Authors:  Svenja Hinderer; Eva Brauchle; Katja Schenke-Layland
Journal:  Adv Healthc Mater       Date:  2015-03-16       Impact factor: 9.933

10.  Priming mesenchymal stem cells boosts stem cell therapy to treat myocardial infarction.

Authors:  Juliana L Carvalho; Vinicius B A Braga; Marcos B Melo; Ana Carolina D A Campos; Maira S Oliveira; Dawidson A Gomes; Anderson J Ferreira; Robson A S Santos; Alfredo M Goes
Journal:  J Cell Mol Med       Date:  2013-03-14       Impact factor: 5.310
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.